Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Sarcoma 2

Conditions

Neuroblastoma 42Glioblastoma 38Brain Neoplasms 33Glioma 31Central Nervous System Neoplasms 27Gliosarcoma 22Astrocytoma 22Oligodendroglioma 16Medulloblastoma 13Neoplasms 12Rhabdomyosarcoma 7Osteosarcoma 7Recurrence 6Ependymoma 5Diffuse Intrinsic Pontine Glioma 5Sarcoma, Ewing 4Optic Nerve Glioma 4Ganglioneuroblastoma 4Familial ependymoma 4Breast Neoplasms 4Sarcoma 3Rhabdoid Tumor 3Pinealoma 3Pancreatic Neoplasms 3Neurologic Manifestations 3Neuroectodermal Tumors, Primitive, Peripheral 3Colonic Neoplasms 3Choroid Plexus Neoplasms 3Bone Neoplasms 3Wilms Tumor 2

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 12Cyclophosphamide 12Radiotherapy 11Bevacizumab 10Filgrastim 9Biopsy 8Carboplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Cisplatin 6Carmustine 6Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4olaparib 3etoposide phosphate 3Vincristine 3Surveys and Questionnaires 3Lapatinib 3Gadolinium DTPA 3Azacitidine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Ependymoma × Irinotecan × CNS × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

NCT00352521 2014-07-22

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Duke University

Phase 2 Completed
20 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00463203 2011-06-29

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Rigshospitalet, Denmark

Phase 2 Completed
54 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡